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A Ab bs st tr ra ac ct t
The impact of commercialization and patenting pressure on genomics research is still a topic of
considerable debate in academic, policy and popular literature. We interviewed genomic
researchers to see if their perspectives offered fresh insights. Regional Genome Canada centers
provided us with relevant researcher contact information, and in-depth structured interviews
were conducted. Researcher perspectives were sharply divided, with both support and concern
for commercialization regimes surfacing in interviews. Data withholding and publication delays
were commonly reported, but the aggressive enforcement of patents was not. There are parallels
to the Stem Cell community in Canada in these respects. Genomic researchers, as individuals
directly implicated in the field of controversy, have developed varied and often novel insights
which should be incorporated into the ongoing debates surrounding commercialization and
patenting. Many researchers continue to raise concerns, particularly in relation to data
withholding, thus emphasizing the need for a continued exploration of the complex issues
associated with commercialization and patenting.
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B Ba ac ck kg gr ro ou un nd d
Concern about the impact of commercialization pressure
on the research environment can be found in both the
academic and popular literature [1-4] - and for good
reason. For example, there is evidence that commercial
influences can increase the rate of information withholding
among researchers [5-8] and encourage selective reporting
of research outcomes unfavorable to industry [7,9-13]. In
addition, close links with industry can erode public trust in
both the research being done and the individuals who are
doing it ([14]; for an extended discussion of the political
and scientific importance of public trust, see [15]).
There is also concern about commercialization in genetics,
particularly in the context of patenting. Gene patents have
come under intense criticism in the media [16-18] and in
the academic community [19-22], and they have been the
subject of numerous policy reports [23-25]. Surveys of the
public indicate that popular opinion is also largely
negative [26]. Although recent research has reduced some
of the concerns associated with gene patents [27-29],
concerns remain and have, in fact, motivated calls for
policy reform [25].
Here, we seek to provide further insights regarding the
perceptions of a key group of stakeholders: genomic
researchers. Building on the relevant survey work that has
been done in other jurisdictions [28,29] and in other
related areas of research [30], we conducted a series of in-
depth structured interviews with leading Canadian
genomics scientists on the topic of commercialization and
gene patenting with the hope that their perspectives would
provide fresh insights to help advance a debate that has
sometimes fallen into stock arguments.A Ap pp pr ro oa ac ch h
We contacted regional Genome Canada centers (Genome
Alberta, Genome BC, the Ontario Genomics Institute,
Genome Quebec and Genome Atlantic) and asked them to
provide contact information for all principal investigators,
co-investigators and collaborators. Key researchers were
then selected from each center on the basis of seniority and
success, in approximate proportion to the relative popula-
tion of the area in question. Some referrals and substitutions
were made to ensure that the contacted sample was appro-
priately representative.
Interviews were conducted by phone and responses were
transcribed. A series of structured items analogous to a
questionnaire were administered in order to provide a basic
understanding of the demographic landscape of our sample
(Additional data file 1). These items had been developed in
tandem with a more traditional survey instrument on the
topic of commercialization administered separately to the
Stem Cell Network [30], which, as shown below, provides
new comparative insights when paired with this study.
Interspersed with these structured items were more open-
ended, qualitative items, which allowed the researchers
interviewed to speak at length about their outlooks on the
interview topics. Although the structure guided the course of
the interviews, a dialog approach was used throughout to
emphasize individual perspectives.
In total, 70 researchers were contacted for interview and 20
interviews (28.6%) were conducted. Of these, 14 interviews
were with Genome Canada principal investigators, four with
co-investigators, and two with collaborators. Respondents
most frequently identified their Genome Canada-related
research efforts as pertaining to human genomics (15, 75%),
followed by genomics and non-human model species (five,
25%), and genomics and agriculture (three, 15%). When
provided with a selection of descriptive epithets,
researchers most often described their work as ‘basic’ (11,
55%), followed by ‘translational’ (eight, 40%) and ‘applied’
(seven, 35%). Respondents often do their work in multiple
contexts, the most popular of these being university
laboratories (14, 70%), followed closely by academic
medical centers (12, 60%).
Although it involves a relatively small sample, the goal of
this study was not to provide exhaustive scope, but rather to
focus in depth on a key group of stakeholders in order to
survey perspectives and elicit novel insights that will help
move the ongoing debate surrounding commercialization
forwards. The existence of Genome Canada, as a major
funder of large-scale genomic research, provided a unique
opportunity to locate and engage this relatively small group.
Moreover, because Genome Canada has a strong knowledge
translation mandate [30], many of these researchers had
considered these issues before they were interviewed, and
had well-developed, unorthodox perspectives that emerged
in their responses.
R Re es su ul lt ts s
Almost all the researchers surveyed stated that the most
important factors motivating their research careers were
high quality of research, the ability to obtain research
funding, and academic integrity. Publication record and peer
recognition were rated very high on the scale of importance,
whereas factors such as monetary gain and the development
of inventions or a patenting record were rated moderately
important or not important at all.
The largest group of researchers (nine, 45%) found patents
to have an overall neutral impact on the research environ-
ment, seven felt that they had an overall negative impact,
and four felt they had an overall positive impact (Figure 1).
Driving the sentiment that patents had a negative impact
was the claim that researchers may be unable to obtain
permission to use patented technologies (all seven found this
important or very important). Researchers were even
occasionally sympathetic to the criticisms found in media
coverage of the gene patent controversy; one researcher
commented: “The problem with patenting biological infor-
mation is that discovered mutations are patented, not just
created mutations.”
Among the reasons for endorsing the use of patents,
however, the reason most cited was the claim that patents
facilitate development of technologies for use by society
(all four of the researchers who maintained patents had a
positive impact found it important or very important). One
researcher suggested that patents, contrary to public
opinion, might in fact have a role in the public
accountability of scientists: “There are very few cases that
an academic has ever seen anything in financial terms
[from a patent], but if you see them as having a
responsibility in their use of public funds, then patenting is
crucially important for it to reach full commercial
potential.”
Nevertheless, patenting and commercial expectation did
seem to have some adverse effects. The potential to patent
was perceived to have caused a delay of research results for
eight researchers (40%), whereas it was said to have caused
the withholding of research information for 11 researchers
(55%). Respondents referred to “vague and unspecific”
conference abstracts or web updates as instances of data
withholding - the implication being that concern about
patentability caused the withholding of more detailed
information. Of those for whom it delayed publication, the
most common delay was by 1-6 months (50%). This pattern
did not surprise one researcher, who found the question
somewhat redundant: “[Patenting] has to [cause withhold-
ing] by definition: if you go out and talk about it, it’s not
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Although publication delays and data withholding were
acknowledged by researchers, only one researcher had
refused to license patented technology to someone who
approached them with a request for a license (5%), citing
as a reason for refusal that “the technology would not be
well used by the recipient”. Similarly, only one researcher
had been refused a license to a patented technology they
needed for research themselves; in response, they worked
around the patented technology by using alternative
methods and approaches. None had ever been served a
‘cease and desist’ letter informing them that they had
infringed a third party’s intellectual property and
instructing them to stop all infringing activities or face
legal action. We can infer from these results that the
researchers’ research work itself had never been delayed
much by another’s patent.
This was certainly not because their particular type of
work did not involve patents: most researchers surveyed
were involved in commercialization activities. Some 65%
of researchers had, at some point, needed to access
patented technology from another party, and exactly half
of the researchers interviewed had themselves been
named as inventor on granted patents or on pending
patent applications. All of those who had been named on a
granted patent (including pending patent applications)
had negotiated license agreements to permit others to use
their technology, most often with private companies.
Overall, 13 researchers maintained that the pressure that
they are currently under to commercialize is reasonable,
and five held that it is unreasonable. Two researchers
declined to respond. One said: “It is reasonable under the
circumstances but I don’t like the circumstances.” Another
respondent insisted that commercialization pressure helps
to boost researcher morale, providing as it does a “real
application” for the research that is being done, and thus
improving work.
When researchers were given the opportunity to speak
openly on the issue of commercialization, interesting and
fresh perspectives consistently emerged. It might be, volun-
teered one researcher, that popular concern is not so much
over commercialization per se as it is over commercial
timelines: “The discovery horizon is much further beyond
the commercial horizon. The commercial horizon is to make
money within 3-5 years, but the discovery horizon is 8-10.
So [the goal should be to make] pressure for commerciali-
zation more commensurate with the discovery horizon.”
Similarly, a different researcher speculated that many of the
problems people supposedly have with commercialization
are in fact problems with inefficient technology transfer
offices (TTOs). “If you could promise a week turnaround
time from a TTO, you would find that virtually no-one was
complaining about delays.”
An older researcher, however, claimed that, despite all
reports of a paradigm shift, things have not changed
much in the past few decades: “All money comes with
strings, whether it’s a requirement to succeed
scientifically or [to help produce] commercial success.”
Both requirements from this perspective could arguably
produce problems.
Another respondent suggested that there is still a disconnect
between the rhetoric surrounding commercialization and its
actual implementation in the laboratory setting, reflected
in the fact that hiring standards are still overwhelmingly
focused on publication record: “The academic ideal has
always been not to pay attention to commercialization.”
A different respondent complained that trying to teach
students to be good scientists in today’s environment is
difficult, because idealistic lessons in scientific integrity
are always contrasted with the realities of the
commercial world, where one finds “exactly the
opposite”. Still another argued that, whether pressures
were currently seen as reasonable or unreasonable,
commercialization is here to stay, and the laboratory had
best adapt to it, contending that it would be
“mythological to think that we will have a large body of
new knowledge that will be freely available.”
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Pie chart showing the opinions of the researchers interviewed on the
overall impact of patents on the research environment.
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It is clear that the opinions of researchers on this topic are
sharply divided, and our interviews were a fruitful explora-
tion of these perspectives. Significantly, aside from evidence
of data withholding and delayed publication, the interviews
uncovered few concrete negative experiences or anecdotes
caused by commercialization. This finding is in keeping with
much of the most recent research on the topic [28,29] and is
also remarkably similar to the results of a similarly
structured survey we administered to the broad membership
of the Stem Cell Network [30]. The stem-cell community and
the genomics research community, though both working in
the face of controversy surrounding emerging technologies,
face very different issues, and it is not at all clear that results
from the two communities on similar issues would be
similar. The fact that they are similar is noteworthy.
In our study and other recent research [28-30], much
concern is expressed about commercialization and patents,
but little is said to suggest that the progress of research itself
is in fact being seriously hindered. Likewise, there is little
evidence that gene patents are being aggressively enforced -
as evidenced by the fact that this group of very active
researchers has had almost no exposure to the enforcement
of patent rights (again, this is consistent with other literature
[31]). The area of data withholding deserves further investi-
gation, as this has been consistently identified as an issue
[1,6] and our research provides some tentative support for
its existence. However, other research has found that other
factors, such as academic competitiveness, may be a more
pronounced source of data withholding behavior [28].
These interviews are exploratory in nature and, of course,
the approach has limitations. Interviews of this nature are
measurements only of perspective, and even then only of a
small sample size. But the window they provide into these
often neglected outlooks is valuable. It should also be noted
that because Genome Canada has a strong interest in
knowledge translation through commercialization [32], this
group of researchers, by holding a Genome Canada grant,
might be viewed (correctly or incorrectly) as having a bias
toward a commercialization ethos. Although this should be
considered in the interpretation of our results, it is worth
noting that despite this potential bias, we still found a
remarkably diverse spectrum of views.
The commercialization of the research environment continues
to stir debate. The degree to which commercial interests
influence outcomes, reporting, the teaching environment
and scientific integrity in the area of genomic research thus
deserves further scrutiny. As one respondent suggested, the
apparent lack of pejorative data on commercialization might
reflect more the structure and timing of the research itself
than the landscape of genomics research: “Most researchers
don’t think about the questions that you’re asking until they
try to move the technology into the private sector.
Universities are developing commercialization offices and
want researchers to do this. The results of [these kind of
investigations] are going to make it look like everything is
hunky-dory when in fact it isn’t.”
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file 1 contains the structured interview instrument, which
was administered to all respondents.
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